VANCOUVER , May 26, 2020 /PRNewswire/ — NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) (“NewLeaf Brands” or the “Company“) is pleased to announce that it has officially appointed Dr. Aubrey Oliver ND, RBT to be its newest advisor. Dr. Oliver is a Jamaican registered Functional Holistic doctor and a graduate of Ashford University in Complementary and Alternative Medicine.
In recent years, Dr. Oliver was the Coordinating Physician with Caribbean Clinical Research Associates on the first clinical research of its kind which dealt with CBD oil, nano liposome, and alcohol-based forms to find out the absorbency efficacy on healthy cells. Additionally, Dr. Oliver is a certified bioenergetics therapist for cell regeneration and rejuvenation while activating the patient’s own stem cells. He is a healing arts specialist with an interest in cannabis and phytonutrients and focuses on a holistic approach towards adrenal exhaustion and aging issues, oncology, infectious diseases and biotoxin illnesses, as well as blood sugar and blood pressure issues.
Damon Michaels , co-founder of Mydecine and COO of NewLeaf, remarked that “We believe working with Dr. Oliver is going to help us expand the cutting edge of Mydecine in many ways. With Dr. Oliver’s extensive knowledge for treating people with homeopathic medicine, developing research groups, and understanding unique route administration, we will be able to take the fungi formulations in development to a whole new level.”
Dr. Oliver is a strong, well-known member of the Jamaican community and will be working with Mydecine to find ways for the Company to expand its efforts into the Caribbean nation.
Dr. Oliver remarked that “I’m grateful and humbled to be announced as an advisor with Newleaf Brands. Over the years, I have been looking for the right vehicle to be able to make a powerful healing impact on my beloved island nation of Jamaica . When I understood the path that Newleaf Brands was going down to advance medicine in order to help many, it was a no brainer for me to join this innovative group. I am happy to now be a key asset to contribute to developing things like a treatment facility and setting up a program for patients and clinicians in our beautiful paradise.”
About NewLeaf Brands
NewLeaf Brands Inc. is the parent company operating innovative product divisions in the Naturally Sourced Therapies (NST) space. While controlling a variety of Psilocybin and hemp-derived CBD brands that design, manufacture and distribute cutting edge products, NewLeaf Brands Inc. further enhances its portfolio with numerous cultivation properties, retail locations, and other land assets.
NewLeaf Brands Inc. is the progressive and innovative Naturally Sourced Therapies (NST) lifestyle group known around the globe. Focusing on the rapidly emerging psilocybin and psychedelic medicines market, the Company’s wholly-owned subsidiary 1220611 B .C. Ltd. (operating as Mydecine Group) (“Mydecine”) is a vertically integrated company engaged to utilize the vast medicinal, health and wellness capabilities of the various compounds found in mycology as a whole. Established to parallel the early emergence of the industry, Mydecine aims to be a pioneer in the cultivation, processing, product development, and research and development of mycology’s exciting compounds through its three divisions, “Mydecine Farms,” “Mydecine Wellness” and “Mydecine Labs.” Furthermore, the Company’s wholly-owned subsidiaries in the hemp-derived CBD space, We are Kured LLC, Drink Fresh Water LLC, Relyfe Brand LLC, Fresh Water CBD LLC and TeaLief Brand LLC have quickly developed into market leaders and maintain extensive retail and cultivation land investments in the United States .
On Behalf of the Board of Directors
Chief Executive Officer
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to completion of planned improvements at both the Canadian and US sites on schedule and on budget, the availability of financing needed to complete the Company’s planned improvements on commercially reasonable terms, planned occupancy by the tenant-growers, commencement of operations, differences in yield on expected harvests, delays in obtaining statutory approval for marijuana production plans, issues that may arise throughout the grow period, outdoor crops affected by weather, the ability to mitigate the risk of loss through appropriate insurance policies, and the risks presented by federal statutes that may contradict local and state legislation respecting legalized marijuana. There are no assurances that the business plans for NewLeaf described in this news release will come into effect on the terms or time frame described herein. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
This news release does not constitute an offer of securities for sale in the United States . These securities have not and will not be registered under United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to a U.S. Person unless so registered, or an exemption from registration is relied upon.
For Further Information Contact
View original content:http://www.prnewswire.com/news-releases/repeat-newleaf-brands-announces-newest-newleaf-brands-advisor-appointee-dr-aubrey-oliver-set-to-spearhead-jamaican-based-psilocybin-healing-retreat-efforts-301065090.html
SOURCE NewLeaf Brands Inc.